Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsty Hodgson

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Dermatologic Clinics|November 29, 2016
Understanding Inherited Cylindromas: Clinical Implications of Gene DiscoveryAnna Dubois, Kirsty Hodgson, Neil Rajan
Biorxiv : the Preprint Server for Biology|April 27, 2026
Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancerKirsty Hodgson, Libby Blencoe, Erin Smith, et al.
Pathology International|June 23, 2026
Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate CancerKirsty Hodgson, Libby Blencoe, Erin Smith, et al.
Nature Communications|October 19, 2019
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndromeHelen R Davies, Kirsty Hodgson, Edward Schwalbe, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Oncogene|June 18, 2026
The glycobiology of prostate cancer: an updateKirsty Hodgson, Margarita Orozco-Moreno, Ziqian Peng, et al.
Cancers|September 14, 2024
Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer CellsEmily Archer Goode, Margarita Orozco-Moreno, Kirsty Hodgson, et al.
JAMA Dermatology|June 30, 2018
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical TrialMarina Danilenko, Elaine Stamp, Deborah D Stocken, et al.
Scientific Reports|October 9, 2023
The role of GCNT1 mediated O-glycosylation in aggressive prostate cancerKirsty Hodgson, Margarita Orozco-Moreno, Emma Scott, et al.
Glycobiology|October 17, 2023
Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitorsMargarita Orozco-Moreno, Eline A Visser, Kirsty Hodgson, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Dermatologic Clinics|November 29, 2016
Understanding Inherited Cylindromas: Clinical Implications of Gene DiscoveryAnna Dubois, Kirsty Hodgson, Neil Rajan
Biorxiv : the Preprint Server for Biology|April 27, 2026
Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancerKirsty Hodgson, Libby Blencoe, Erin Smith, et al.
Pathology International|June 23, 2026
Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate CancerKirsty Hodgson, Libby Blencoe, Erin Smith, et al.
Nature Communications|October 19, 2019
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndromeHelen R Davies, Kirsty Hodgson, Edward Schwalbe, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Oncogene|June 18, 2026
The glycobiology of prostate cancer: an updateKirsty Hodgson, Margarita Orozco-Moreno, Ziqian Peng, et al.
Cancers|September 14, 2024
Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer CellsEmily Archer Goode, Margarita Orozco-Moreno, Kirsty Hodgson, et al.
JAMA Dermatology|June 30, 2018
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical TrialMarina Danilenko, Elaine Stamp, Deborah D Stocken, et al.
Scientific Reports|October 9, 2023
The role of GCNT1 mediated O-glycosylation in aggressive prostate cancerKirsty Hodgson, Margarita Orozco-Moreno, Emma Scott, et al.
Glycobiology|October 17, 2023
Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitorsMargarita Orozco-Moreno, Eline A Visser, Kirsty Hodgson, et al.
Pageof 2